CONCLUSION
dengue
DENGUE
In conclusion, the available data suggest that TAK-003 vaccination resulted in a reduced risk of experiencing sequential episodes of symptomatic dengue in children and adolescents age 4 to 16 years in dengue-endemic areas. These data indicate some potential benefit even in vaccine recipients who might experience breakthrough symptomatic dengue.